<DOC>
	<DOCNO>NCT01352091</DOCNO>
	<brief_summary>The present study randomize open-label -phase III study aim compare efficacy Zoladex® combine Aromidex® 3-2 year SERMs ( tamoxifen Fareston® ) adjuvant therapy 2-3 year efficacy tamoxifen 5 year premenopausal breast cancer woman hormone receptor positive , lymph node positive tumor ≥4cm . According St. Gallen 's guideline , hormone receptor positive defined endocrine responsive endocrine response uncertain category ( table 3-1 ) , ER PR expression undetectable consider HR negative . The pathological evaluation axillary lymph node could do sentinel node biopsy ( SNB ) axillary node clinically impalpable accompany axillary lymph node dissection ( ALND ) directly ALND axillary node appear positive clinical examination . Based operate standard local medical institution , identify number lymph nodes pathological evaluation dissection I- II-station node accurately .</brief_summary>
	<brief_title>Adjuvant AI Combined With Zoladex</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>1 . All patient must sign date informed consent form 2 . Patients must female 3 . Primary invasive breast cancer pathologically approve core needle open biopsy 4 . Ipsilateral axillary internal mammary node positive , tumor size equal large 4cm . Definition node positive accord stag system AJCC 6th edition ( American Joint Cancer Commission ) breast carcinoma . The micrometastasis must least 0.2mm 5 . Patients must undergo standard surgery primary breast cancer show follow : standard radical mastectomy modify mastectomy standard breast conservation surgery ( BCS ) , lumpectomy qaudrantectomy accompany axillary dissection , surgical margin resect specimen must negative . BCS must follow standardized adjuvant radiotherapy partial conserve breast ( deliver adjuvant chemotherapy complete ) Treatment confirm breast cancer include surgery modality list , locoregional radiotherapy lumpectomy , adjuvant radiotherapy chest wall and/or internal mammary node and/or supraclavicular lymph node , adjuvant chemotherapy 6. adjuvant endocrine therapy TAM Fareston must start within 6 week adjuvant chemotherapy radiotherapy finish 7 . The date randomization must process take TAM Fareston 2 2 year , 3 year time 8 . Patients take neochemotherapy eligible , lymph node status could identify surgery neoadjuvant chemotherapy neoadjuvant chemotherapy . The definition lymph node positive : evaluation lymph node status neoadjuvant chemotherapy must include pathological axillary node , internal mammary node ( pN2b option ) supraclavicular node ( pN3c option ) involve . Micrometastasis ( i.e.≥0.2mm , pN1pN3c ) identify follow method : fine needle aspiration ( FNA ) sentinel node biopsy ( SNB ) sampling/ total procedure axillary dissection patient node positive neoadjuvant chemotherapy , lymph node positive must evaluate surgery . Its definition either following : According clinical practice guideline local cancer center , acceptable positive node identify SNB axillary dissection There pathological evidence lymph node positive ( pN1pN3c ) breast surgery neoadjuvant chemotherapy 9 . Patients diagnose occult breast cancer clinically find pathologically primary invasive carcinoma DCIS microinvasive lesion ipsilateral breast , primary lesion axillary node metastasis express ER and/or PR positive 10 . Patients synchronous bilateral cancer eligible condition If one side IDC side DCIS , IDC side ER and/or PR positive phenotype IF two side IDC , must ER and/or PR positive phenotype time 11 . Hormone receptor positive ( ≥＋ ) define detect ER PR expression time eligible . The situation PR positive ER negative eligible , 12 . According standard operation principle clinical practice local cancer center , patient must randomize within 4 week definitive physical examination , image examination laboratory test show evidence recurrence metastasis 13 . Based study objective , patient require premenopausal define menstruate actively less 6 month since last menstrual period ( LMP ) , patient young 40 year age become amenorrheic 1 year serum free E2、FSH LH level premenopausal ( accord reference value local center ) . previous hysterectomy one ovaries leave intact eligible serum free E2、FSH LH level premenopausal ( accord reference value local center ) . 14. patient must ECOG performance status 0 1 ( 0fully active , able carry predisease performance without restriction , 1restricted physical strenuous actively ambulatory ) 15. leucocyte count must ≥3.0*10^9/L platelet count must ≥100*10^9/L 16 . AST/SGOT ALT/AGPT must &lt; 3 time ULN 17. serum creatinine must &lt; 2 time ULN 18. patient swallow pill 19. pregnancy test negative willing contraception treatment period 1. patient metastatic malignant tumor 2. previous history asynchronous bilateral breast cancer 3. previous malignancy past 5 year , except treat curative intent , carcinoma situ cervix , squamous carcinoma skin basal cell carcinoma skin 4. nonmalignant systemic disease interfere long time follow 5. history medical ovarian ablation therapy 6. history AI therapy 7. severe live dysfunction , Child－Pugh grade C 8 . Occult breast cancer find pathologically IDC lesion DCIS without microinvasive lesion ipsilateral breast 9. patient Her2 overexpression use , use , intend use adjuvant trastuzumab 10. severe heart dysfunction , heart functional classification Class III Table 2 ChildPugh score hepatic cirrhosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant endocrine therapy</keyword>
	<keyword>AI</keyword>
	<keyword>Zoladex</keyword>
</DOC>